Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...

On Friday, the U.S. District Court for the District of Maryland paused several parts of a health insurance exchange enrollment and eligibility rule that was set to take effect today. The court agreed ...

Gilead Sciences (($GILD)) announced an update on their ongoing clinical study. Gilead Sciences is currently conducting a Phase 3 clinical study ...

At Martha’s Vineyard, Touch Talks Wellness and BlackDoctor.org joined forces to host an urgent and deeply personal conversation on cancer disparities in the Black community. Powered by partnerships ...

Interius is working on a more efficient way to deliver CAR-T therapy to patients. Unlock Digital Access for unlimited access to Inquirer.com and The Inquirer App, plus 5 articles per month to gift to ...

Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.

Gilead Sciences agreed to buy Interius BioTherapeutics, a privately held biotechnology company developing in-vivo CAR therapeutics, for $350 million. Gilead on Thursday said the deal complements the ...

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading below its intrinsic value. See more.

Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s what investors should know.